Posted by Michael Wonder on 15 Sep 2020
US FDA grants fast track designation to Jardiance (empagliflozin) to improve outcomes following a heart attack
15 September 2020 - This fast track designation for empagliflozin emphasises the urgent need for potential treatments that may improve outcomes following an acute myocardial infarction, more commonly known as a heart attack, in adults with and without diabetes.
The U.S. FDA has granted fast track designation for the development of Jardiance (empagliflozin) to prevent hospitalisation for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction (more commonly known as a heart attack), Boehringer Ingelheim and Eli Lilly and Company announced.
EMPACT-MI (A Streamlined, Multicenter, Randomized, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction) is investigating the effect of Jardiance on all-cause mortality and hospitalisation for heart failure in adults with and without type 2 diabetes who have had an acute myocardial infarction and no history of chronic heart failure.
